Cited by 6,068COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchCOVID-19 epidemiological studies

The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges

Open access
Lai, Chih-Cheng, Shih, Tzu-Ping, Ko, Wen-Chien, Tang, Hung-Jen, Hsueh, Po-Ren·2020·International Journal of Antimicrobial Agents

Abstract

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; previously provisionally named 2019 novel coronavirus or 2019-nCoV) disease (COVID-19) in China at the end of 2019 has caused a large global outbreak and is a major public health issue. As of 11 February 2020, data from the World Health Organization (WHO) have shown that more than 43 000 confirmed cases have been identified in 28 countries/regions, with >99% of cases being detected in China. On 30 January 2020, the WHO declared COVID-19 as the sixth public health emergency of international concern. SARS-CoV-2 is closely related to two bat-derived severe acute respiratory syndrome-like coronaviruses, bat-SL-CoVZC45 and bat-SL-CoVZXC21. It is spread by human-to-human transmission via droplets or direct contact, and infection has been estimated to have mean incubation period of 6.4 days and a basic reproduction number of 2.24-3.58. Among patients with pneumonia caused by SARS-CoV-2 (novel coronavirus pneumonia or Wuhan pneumonia), fever was the most common symptom, followed by cough. Bilateral lung involvement with ground-glass opacity was the most common finding from computed tomography images of the chest. The one case of SARS-CoV-2 pneumonia in the USA is responding well to remdesivir, which is now undergoing a clinical trial in China. Currently, controlling infection to prevent the spread of SARS-CoV-2 is the primary intervention being used. However, public health authorities should keep monitoring the situation closely, as the more we can learn about this novel virus and its associated outbreak, the better we can respond.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ijantimicag.2020.105924

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

Sorted by citations

See all 6,068

Metadata

Authors
Lai, C.-C., Shih, T.-P., Ko, W.-C., Tang, H.-J., & Hsueh, P.-R.
Affiliations
  • Kaohsiung Veterans General Hospital (TW)
  • National Cheng Kung University (TW)
  • Chi Mei Medical Center (TW)
  • National Taiwan University (TW)
Corresponding author
Hsueh, Po-Ren
Venue
International Journal of Antimicrobial Agents
Publisher
Elsevier BV
Published
2020-03
Volume
55
Issue
3
Pages
105924
ISSN
0924-8579 (ISSN-L)
OpenAlex
W3006645647
Cited by
6,068
References
61
Citations by year
2026: 69 · 2025: 182 · 2024: 351 · 2023: 609 · 2022: 1050 · 2021: 1770 · 2020: 2028
FWCI
179.14
Type
journal article
Language
en
Open access
Locations
  • International Journal of Antimicrobial Agents (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Taiwan University Hospital
Topics
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
Keywords
SARS-CoV-2, COVID-19 pandemic, coronavirus pneumonia, SARS-CoV-2 transmission, incubation period, basic reproduction number, remdesivir, infection control, public health emergencies, ground-glass opacities
MeSH terms
Betacoronavirus, COVID-19, SARS-CoV-2, China, Disease Outbreaks, Humans, Pneumonia, Viral, World Health Organization, Coronavirus Infections, Severe Acute Respiratory Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review